company background image
IBX

Imagion BiosystemsASX:IBX Stock Report

Market Cap

AU$74.3m

7D

0%

1Y

-9.0%

Updated

18 Oct, 2021

Data

Company Financials
IBX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

IBX Overview

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy.

Price History & Performance

Summary of all time highs, changes and price drops for Imagion Biosystems
Historical stock prices
Current Share PriceAU$0.071
52 Week HighAU$0.062
52 Week LowAU$0.23
Beta3.4
1 Month Change5.97%
3 Month Change-17.44%
1 Year Change-8.97%
3 Year Change73.18%
5 Year Changen/a
Change since IPO-55.63%

Recent News & Updates

Sep 09
We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

We're Hopeful That Imagion Biosystems (ASX:IBX) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

May 03
We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

We're Not Very Worried About Imagion Biosystems' (ASX:IBX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, Imagion...

Feb 28
Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

Imagion Biosystems (ASX:IBX) Has Rewarded Shareholders With An Exceptional 582% Total Return On Their Investment

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...

Shareholder Returns

IBXAU Medical EquipmentAU Market
7D0%-0.7%0.9%
1Y-9.0%-4.9%20.2%

Return vs Industry: IBX underperformed the Australian Medical Equipment industry which returned -4.9% over the past year.

Return vs Market: IBX underperformed the Australian Market which returned 20.2% over the past year.

Price Volatility

Is IBX's price volatile compared to industry and market?
IBX volatility
IBX Beta3.4
Industry Beta0.57
Market Beta1

Stable Share Price: IBX is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: IBX's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2016n/aBob Proulxhttps://imagionbiosystems.com

Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to find and detect cancer.

Imagion Biosystems Fundamentals Summary


Earnings & Revenue

Key profitability statistics from the latest earnings report
IBX income statement (TTM)
RevenueAU$3.17m
Cost of RevenueAU$2.30m
Gross ProfitAU$865.42k
ExpensesAU$5.94m
Earnings-AU$5.08m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.0049
Gross Margin27.34%
Net Profit Margin-160.36%
Debt/Equity Ratio0%

How did IBX perform over the long term?

See historical performance and comparison

Valuation

Is Imagion Biosystems undervalued compared to its fair value and its price relative to the market?

5.46x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IBX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IBX is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: IBX is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IBX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IBX is overvalued based on its PB Ratio (5.5x) compared to the AU Medical Equipment industry average (4.5x).


Future Growth

How is Imagion Biosystems forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.2%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Imagion Biosystems has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Imagion Biosystems performed over the past 5 years?

24.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IBX is currently unprofitable.

Growing Profit Margin: IBX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IBX is unprofitable, but has reduced losses over the past 5 years at a rate of 24% per year.

Accelerating Growth: Unable to compare IBX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (74.9%).


Return on Equity

High ROE: IBX has a negative Return on Equity (-37.3%), as it is currently unprofitable.


Financial Health

How is Imagion Biosystems's financial position?


Financial Position Analysis

Short Term Liabilities: IBX's short term assets (A$14.4M) exceed its short term liabilities (A$1.1M).

Long Term Liabilities: IBX's short term assets (A$14.4M) exceed its long term liabilities (A$40.0K).


Debt to Equity History and Analysis

Debt Level: IBX is debt free.

Reducing Debt: IBX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IBX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IBX has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 8.2% each year.


Dividend

What is Imagion Biosystems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IBX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IBX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IBX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IBX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IBX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Bob Proulx (63 yo)

no data

Tenure

AU$607,577

Compensation

Mr. Robert Romeo Proulx, also known as Bob, has been Chief Executive Officer at Imagion Biosystems Limited since January 12, 2015 and has been its President since February 2015. He serves as Executive Chai...


CEO Compensation Analysis

Compensation vs Market: Bob's total compensation ($USD450.96K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Bob's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: IBX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: IBX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.4%.


Top Shareholders

Company Information

Imagion Biosystems Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Imagion Biosystems Limited
  • Ticker: IBX
  • Exchange: ASX
  • Founded: 2016
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$74.294m
  • Shares outstanding: 1.05b
  • Website: https://imagionbiosystems.com

Location

  • Imagion Biosystems Limited
  • 10355 Science Center Drive
  • Suite 210
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:33
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.